INTRODUCTION
============

Recent studies have revealed that binding specificities of influenza viral hemagglutinins(HA) with sialooligosaccharide receptors are involved in the virus host range determination ([@B39]; [@B20]; [@B35], [@B42]). Avian influenza viruses can bind to avian-type receptor Neu5Acα(2-3)Gal on human airway epithelium ([@B19]) and lower respiratory tract ([@B31]; [@B41]). However, this infection mechanism does not cause pandemic human influenza. We must pay attention to the higher binding affinity of avian viruses to human-type receptor Neu5Acα(2-6)Gal ([@B30]; [@B44]; [@B4]; [@B2], [@B37]). When the binding specificity of mutant influenza viral HA with human α2-6 ligand is predicted in advance, we can take measures against an outbreak of pandemic human influenza. However, a scientific framework for studies to predict changes in the host ranges of influenza viruses has not yet been established. We believe that, with high performance PC cluster, *ab initio* based fragment molecular orbital (FMO) studies of the HA-sialoside complexes will help to predict the chemical properties of HA-sialoside binding ([@B27], [@B28], [@B29]; [@B14]).

Influenza virion attaches to α-sialoglycoproteins and α-sialoglycolipids on the host cell surface via molecular interactions between the viral HA and sialooligosaccharide ([@B3]; [@B13]). HA forms a trimer which has sialoside receptor binding sites on the surface of each HA1 domain ([@B32]). The binding site consists of 130-loop, 150-loop, 190-helix, and 220-loop, and their chemical behaviours allow avian viral HA to interact specifically with the avian Neu5Acα(2-3)Gal receptor ([@B11], [@B12]; [@B9]; [@B34], [@B36]; [@B26]). Amino acid substitutions at the sialoside binding site change HA-sialoside binding properties ([@B18]; [@B10]; [@B44]; [@B40]; [@B1]; [@B43]). In addition, a substitution at HA1 antigenic site D, which is situated far from the sialoside binding site, also alters the relative binding specificity of HA with human/avian-type receptors ([@B38]). These results suggest that mutations on avian viral HA1 can shift the host range of virus from birds to humans, therefore, chemical prediction studies may require quantum chemical analyses of sialoside receptors in complex with the entire HA1 domain. At the same time, we should balance a computational cost with model size of HA1-sialoside complex. However, there is no insight into relationship between the model size of HA1-sialoside complex and its binding energy.

We previously reported the binding energies and interfragment stabilizations between avian H3 and disaccharide analogs of avian- and human-type Neu5Acα(2-3 and 2-6)Gal receptors ([@B29]). In these study, we used small model complex of the binding site (70 amino acids) and conducted FMO calculations at the MP2/6-31G level to evaluate the intermolecular electrostatic interactions and dispersion interactions. However, this approach had to treat sensitively the peptide terminals in the very small binding site models. Recently, with a suitable PC cluster, FMO method was shown to calculate a viral HA-antibody complexes at the MP2 level ([@B21]), as well as HA1 full domain-sialoside complexes.

In the FMO two-body terms method (FMO2), an HA1-sialoside complex is divided into *N* fragments, and molecular orbital calculations are carried out on each fragment (*I, J*,.., *N*) and fragment pairs (*IJ, IK, IL*,...,*JK, JL*,..., (*N*-1)*N*). Next, the total energy E of the entire HA1-sialoside complex is evaluated with the following equation: $$E = {\sum\limits_{\text{I}}^{N}{E_{\text{I}} + {\sum\limits_{\text{I>}J}^{N}{(E_{\text{IJ}} - E_{\text{I}} - E_{\text{J}})}}}}$$ where the terms represent summation of the fragment energies and interfragment interaction energies (IFIEs), respectively ([@B15],[@B16]).

Since the method estimates IFIEs by taking account of many-body corrections ([@B46]; [@B45]), we are able to analyze intermolecular stabilizations of Neu5Ac-Gal receptors with amino acid residues at the sialoside binding site on HA1.

In this study, we applied FMO method to influenza viral HA H3-subtype HA1 full domain complexed with the avian- and the human-type Neu5Acα(2-3 and 2-6)Gal disaccharides. Binding energies between HA1s and sialosides were computed at the FMO2-MP2/6-31G level. We analyzed relationships between HA1-siaoside binding energies and size-dependency of HA1-siaoside complexes. Besides interfragment stabilizations in the two kinds of larger HA1 complexes were compared to give some guidance for future large-scale FMO studies.

MATERIALS AND METHODS
=====================

Computational analysis
----------------------

The H3-receptor complexes for the FMO studies were obtained from the energy minimum structures of avian and human A virus H3-subtype trimers in complex with Neu5Acα(2-3 or 2-6)Gal analogs as reported previously ([@B29]). We clipped small model complex **A**, large-size complex **B**, and full-size HA1 complex **C** from the geometry optimized avian/human H3 complexes ([Figure 1](#F1){ref-type="fig"}). Peptide terminals in the models were treated as NH~3~^+^ and COO^−^ in a similar manner to that used in our previous studies. We computed the single point energies of the whole complexes (*E*~complex~), corresponding to H3 HA1 domains (*E*~H3~), and Neu5Acα(2-3/6)Gal (*E*~receptor~) at the FMO2-MP2/6-31G level, followed by evaluation of H3-sialoside binding energy (ΔE) by the following equation: $$\Delta E = (E_{\text{H3}} + E_{\text{receptor}}) - E_{\text{complex}}$$ The HA1 domains were divided into single amino acid residue as a single fragment (with the exception of Cys SS Cys pairs) using automatic fragmentation scheme in ABINIT-MP package (<http://www.ciss.iis.u-tokyo.ac.jp/fsis/en/index.html>) ([Figure 2](#F2){ref-type="fig"}). Neu5Ac-Gal receptors were treated as a single fragment charged to −1 ([Figure 3](#F3){ref-type="fig"}). To compute neutral H3--sialoside system in gas phase, H3 HA1 domains in the complexes **A-C** were charged to +1 as same manner in our previous studies ([@B27], [@B28], [@B29]), namely several δ-guanidium on Arg and ε-ammonium on Lys were de-protonated to be neutral form ([Table 1](#T1){ref-type="table"}). FMO calculations were carried out using ABINIT-MP program.

![The complexes of influenza A virus H3 HA1 domain with Neu5Ac-Gal analog for the FMO-MP2/6-31G calculations. **A.** The complex has the smallest receptor binding site ([@B27], [@B29]). The site has four peptides Asn96-Pro99, Gly129-Tyr161, Gly181-Val196, and Asn216-Ile232 to be total 70 amino acids. **B.** Binding domain in the complex consists of Arg(Ile)62-Gly263 (202 amino acids, avian H3; Arg62, human H3; Ile62), **C**. The complex has the full size of HA1 domain (avian H3; Ser9-Lys326, human H3; Gln1-Thr328, [@B28]). ribbon model; HA1, red; helix, blue; sheet, CPK model; Neu5Ac-Gal analog.](jmgm-03-133-g001){#F1}

![Schematic fragmentation of H3 HA1 domain. HA1 domain was fragmented by cutting Cα-C bonds in accordance with general manner ([@B7]). Cα were bond detached atoms. Fragment 1, 2,..., *i, i*+1,..., *N* were treated as amino acid residue 1, 2,..., *i, i*+1,..., *N*.](jmgm-03-133-g002){#F2}

![Schematic structures of avian and human receptor Neu5Acα(2-3 and 2-6)Gal](jmgm-03-133-g003){#F3}

###### 

Basic and acidic amino acid residues in the models **A-C**

  H3          model                                        Arg                                                                                                                                                                                         Lys                                                                                                       His[^\*4^](#TFN1-4){ref-type="table-fn"}     terminal NH~3~^+^               Asp                                                                            Glu                                            ternimal COO^-^
  ----------- -------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- -------------------------------------------- ------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------- --------------------------------
  **Avian**   **A**[^\*1^](#TFN1-1){ref-type="table-fn"}   141[^\*3^](#TFN1-3){ref-type="table-fn"}, 150[^\*3^](#TFN1-3){ref-type="table-fn"}, 220, 224[^\*3^](#TFN1-3){ref-type="table-fn"}, 229[^\*3^](#TFN1-3){ref-type="table-fn"}                 140, 156                                                                                                  183(E), 184(E)                               Asn96, Glyl29, Glyl81, Asn216                                                                                  158, 190                                       Pro99, Tyrl61, Val 196, Ile232
              **B**                                        62[^\*3^](#TFN1-3){ref-type="table-fn"}, 90, 109, 141, 150, 201, 207, 208[^\*3^](#TFN1-3){ref-type="table-fn"}, 220, 224, 229, 255, 261                                                     140, 156, 176, 238, 259                                                                                   75(E), 183(E), 184(E)                        Arg62                           68, 73, 77, 85, 101, 104, 172, 175, 241                                        82, 89, 119, 123, 158, 190                     Gly263
              **C**                                        57,62[^\*3^](#TFN1-3){ref-type="table-fn"}, 90, 109, 141, 150, 201, 207, 208[^\*3^](#TFN1-3){ref-type="table-fn"}, 220, 224, 229, 255, 261, 269[^\*3^](#TFN1-3){ref-type="table-fn"}, 321   27, 50, 140, 156, 176, 238, 259, 264, 292, 299, 307, 310, 315, 326[^\*3^](#TFN1-3){ref-type="table-fn"}   17(E), 18(E), 56(E), 75(E), 183(E), 184(E)   Ser9                            31, 32, 60, 68, 73, 77, 85, 191, 104, 172, 175, 241, 271, 275, 291             35, 41, 82, 89, 119, 123, 158, 190, 280, 325   Lys326
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  **Human**   **A**[^\*1^](#TFN1-1){ref-type="table-fn"}   141[^\*3^](#TFN1-3){ref-type="table-fn"}, 150, 220[^\*3^](#TFN1-3){ref-type="table-fn"}, 224[^\*3^](#TFN1-3){ref-type="table-fn"}, 229[^\*3^](#TFN1-3){ref-type="table-fn"}                 140, 156[^\*3^](#TFN1-3){ref-type="table-fn"}                                                             183(E), 184(E)                               Asn96, Glyl29, Glyl81, Asn216                                                                                  190                                            Pro99, Tyrl61, Val 196, Ile232
              **B**[^\*2^](#TFN1-2){ref-type="table-fn"}   90, 109, 141, 150, 201, 207, 208, 220, 224, 229, 255, 261[^\*3^](#TFN1-3){ref-type="table-fn"}                                                                                              92[^\*3^](#TFN1-3){ref-type="table-fn"}, 140, 156, 176, 238, 259[^\*3^](#TFN1-3){ref-type="table-fn"}     75(P), 183(E), 184(E)                        Ile62                           63, 68, 73, 77, 85, 101, 104, 172, 175, 241                                    82, 89, 119, 123, 190                          Gly263
              **C**[^\*2^](#TFN1-2){ref-type="table-fn"}   57, 90, 109, 141, 150, 201, 207, 208, 220, 224, 229, 255, 261 [^\*3^](#TFN1-3){ref-type="table-fn"}, 269[^\*3^](#TFN1-3){ref-type="table-fn"}, 321[^\*3^](#TFN1-3){ref-type="table-fn"}     27, 50, 92, 140, 156, 176, 238, 259, 264, 292, 299, 307, 310, 315, 326                                    17(D), 18(E), 56(E), 75(P), 183(E), 184(E)   Glnl                            2, 7, 31, 32, 60, 63, 68, 73, 77, 85, 101, 104, 172, 175, 241, 271, 275, 291   35, 41, 82, 89, 119, 123, 190, 280, 325        Thr328

Sawada et al, 2006, 2008

Sawada et al, 2007

Side chain δ-guanidium on Arg and ε-ammonium on Lys are neutralized in order to compute neutral H3--sialoside complex.

There are three types of histidine. E; neutral form with NE proton. D; neutral form with ND proton. P; positive charged form with ND and NE protons.

RESULTS AND DISCUSSION
======================

Binding energies between HA1 and Neu5Acα(2-3 and 2-6)Gal receptors
------------------------------------------------------------------

Binding energies (Δ*E*s) of the avian and human H3 complexes **B**, **C** at the FMO-MP2/6-31G level are summarized in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. Avian H3 bound to avian receptor Neu5Acα(2-3)Gal stronger than to human receptor Neu5Acα(2-6)Gal by a value of 15.3-16.5 kcal/mol ([Table 2](#T2){ref-type="table"}; entries 8, 9).

###### 

Binding energies in kcal/mol of avian H3 with avian/human Neu5Acα(2-3/6)Gal receptors

  Entry                           Model   MP2/6-31G
  ------- ----------------------- ------- --------------------------------------------
  1       Δ*E*~α2-3~              **A**   180.4[^\*1^](#TFN2-1){ref-type="table-fn"}
  2                               **B**   204.5
  3                               **C**   200.0
  4       Δ*E*~α2-6~              **A**   169.0[^\*1^](#TFN2-1){ref-type="table-fn"}
  5                               **B**   189.2
  6                               **C**   183.5
  7       Δ*E*~α2-3~-Δ*E*~α2-6~   **A**   11.4[^\*1^](#TFN2-1){ref-type="table-fn"}
  8                               **B**   15.3
  9                               **C**   16.5

These data were previously reported in [@B29].

###### 

Binding energies in kcal/mol of human and avian Gln226Leu H3s with human Neu5Acα(2-6)Gal receptors

  Entry   H3                Model   Δ*E*~α2-6~ MP2/6-31G
  ------- ----------------- ------- --------------------------------------------
  1       Human             **A**   154.3[^\*1^](#TFN3-1){ref-type="table-fn"}
  2                         **B**   190.2
  3                         **C**   203.1
  4       Avian Gln226Leu   **A**   157.6[^\*1^](#TFN3-1){ref-type="table-fn"}
  5                         **B**   177.4
  6                         **C**   172.3

These data were previously reported in [@B29].

Δ*E*s of the larger avian H3 complexes **B** and **C** have 14.5-24.1 kcal/mol larger values than those of small complex **A** ([Table 2](#T2){ref-type="table"}; entries 2, 3, 5, 6) because the former two models take into account long-range electrostatic interactions between Neu5Ac-Gal and charged amino acid residues. With the long-range interaction, energy difference between Δ*E*~α2-3~ and Δ*E*~α2-6~ are 15.3 and 16.5 kcal/mol in the models **B** and **C** ([Table 2](#T2){ref-type="table"}; entries 8, 9). These results suggest that model **B** has enough size for the binding energy calculation at the FMO-MP2 level. Consideration of more real HA trimer-sialoside system, trimerized model **B** may give an accurate binding energy with FMO method. Model **B** involves antigenic sites A, B, D, and E ([@B33]).

In the human H3--human α2-6 complex, full model **C** has a highest Δ*E*~F2-6~ 203.1 kcal/mol, which is about 50 and 36 kcal/mol larger than those of models **A** and **B** ([Table 3](#T3){ref-type="table"}; entries 1-3). In addition, energy difference in Δ*E*~α2-6~ between human H3 complex **A** and **B** ([Table 3](#T3){ref-type="table"}; entries 1, 2) is 15-16 kcal/mol larger than the corresponding differences in the avian H3 complexes ([Table 2](#T2){ref-type="table"}; entries 4, 5. [Table 3](#T3){ref-type="table"}; entries 4, 5). These data indicate that human H3 differs from avian H3 in terms of the relationship between Δ*E*~α2-6~ and model structure, whose details are discussed by IFIE analysis in next section. Here we note that monotonous increase of Δ*E*~α2-6~ in the human H3 complex is probably a pretense ([Table 3](#T3){ref-type="table"}; entries 1-3) because the Δ*E*~α2-6~ does not simply increase at the FMO-RHF/STO-3G level as the model complex became larger ([@B28]).

Gln226Leu substitution on avian H3 changes the binding specificity from avian α2-3 to human α2-6 ([@B25]). In the smallest model **A**, Δ*E*~α2-6~ of avian Gln226Leu H3 complex is quite similar to that of human H3 complex ([Table 3](#T3){ref-type="table"}; entries 1, 4. [@B29]). However, the similarity is lost as the model size becomes larger ([Table 3](#T3){ref-type="table"}; entries 2, 3, 5, 6). Their details are discussed by IFIE analysis in next section.

In this section, we have analyzed a relationship between HA1-siaoside binding energy in gas phase and size-dependency of HA1-siaoside complex with charged amino acid residues. Avian H3 HA1 binds to avian α2-3 receptor 15.3-16.5 kcal/mol more strongly than to human α2-6 receptor in gas phase, and this binding benefit is larger than corresponding in small model complex. Avian H3 HA1 differs from human H3 in terms of the relationship between Δ*E*~α2-6~ and model structure. To obtain more accurate total energies and binding energies of HA1-sialoside complexes, we will apply the following approaches in the near future: \[a\] Fragmentation of HA1 domain into larger blocks, *e.g.*, two amino acid residues as a fragment ([@B23]; [@B8]; [@B22]), \[b\] Applying larger basis sets, such as 6-31(+)G(d), where diffuse function was added on the negative charged groups COO^-^, \[c\] Correlation of basis set superposition error, \[d\] QM/MM or multilayer FMO ([@B6]) geometry optimization of HA1-sialoside complex with explicit water solvent after structural equilibrations are carried out by molecular dynamics simulations, \[e\] Utilizing more approvable expressions to calculate the binding energy of protein with ligand ([@B23]; [@B22]), \[f\] Major part of larger binding energy in gas phase should be correlated by de-solvation enegy ([@B22]).

Mainly, binding free energy of HA to sialoside in aqueous phase governs HA-sialoside binding affinity ([@B5]; [@B24]; [@B17]). To evaluate the binding free energy, many elements in the thermodynamic cycle of binding free energy are calculated by using various approximations and computational methods ([@B22]). FMO-MP2 calculations can provide enthalpic energies of the HA-sialoside complex, isolated HA, and sialoside receptor as some elements in the thermodynamic cycle. However, for *in silico* predictions of the avian HA mutant-human α2-6 binding, we require a simple and qualitative framework.

In order to establish the appropriate framework, we propose a trial such that *in silico* simulations are utilized to estimate various kinds of differences (Δ values) between the original avian HA-human α2-6 binding (control) and HA mutant-human α2-6 bindings, where Δ values are *e.g.*, relative binding energies of HA mutants to α2-6 ligand, relative interfragment stabilizations, and relative flexibilities of HA mutant-human α2-6 complexes. Since recent experimental studies have revealed binding properties of original avian HA and its mutants to human α2-6 receptor, *in silico* simulation of the reported avian HA-human α2-6 systems will afford a reliable relationship between Δ values and mutation positions on HA1 domain. This approach avoids computing the binding free energy. Instead, we need to adopt chemical intuition to select suitable Δ values. The Δ values should satisfy some requirements, such as approximate independence each other, relation to the binding free energy, and needless large-sized sampling. In the future, we will develop the concept, and attempt to find the Δ values using MD simulation, QM/MM calculation, and FMO-MP2 studies.

Analysis of interfragment interaction energies between Neu5Acα(2-3 and 2-6)Gal and amino acids on HA1
-----------------------------------------------------------------------------------------------------

In the above section, we have mentioned that human H3 differs from avian H3 in terms of the relationship between Δ*E*~α2-6~ and model structure ([Table 2](#T2){ref-type="table"}; entries 4, 5, [Table 3](#T3){ref-type="table"}; entries 1, 2), besides there is no similarity of Δ*E*~α2-6~ between human Leu226 H3 complex and avian Gln226Leu H3 complex in the model **B** ([Table 3](#T3){ref-type="table"}). These results are explained by analysis of IFIEs between Neu5Acα(2-6)Gal and amino acid residues on H3 in the models **A** and **B** ([Table 4](#T4){ref-type="table"}). Charged amino acid residues strongly interacts with negative charged Neu5Acα(2-6)Gal, and whose interaction energies affect the human 2-6-H3 binding energy. Since expanding model size from complex **A** to **B** with neutral HA-sialoside system demands us to de-protonate and re-protonate amino acid side chain -guanidium on Arg and -ammonium on Lys, modification of model **A** range in the human H3 model **B** quite differs from that of avian H3 complex ([Table 1](#T1){ref-type="table"}; lines Arg and Lys). Thus, in terms of the relationship between Δ*E*~α2-6~ and model structure, human H3 has a different tendency from the corresponding avian H3 ([Table 4](#T4){ref-type="table"}; entries 9, 12). Avian Gln226Leu H3 has the same tendency as avian Gln226 H3 that causes the non-similarity of Δ*E*~α2-6~ between avian Gln226 H3 and human Leu226 H3. Comparing amino acid sequence of avian H3 with human H3 shows four substitutions at 62, 63, 92, and 102 on the model **B** range excluding the range of model **A** ([Figure 4](#F4){ref-type="fig"}), then the charged residues affect H3-sialoside binding energies ([Table 4](#T4){ref-type="table"}; entry 14). Expanding model size from **B** to **C** decreases the Δ*E*~α2-6~ by \#x223C;5.1-5.7 kcal/mol in the avian H3 complexes ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}; entries 5, 6), but increases 13.1 kcal/mol in human H3 complex ([Table 3](#T3){ref-type="table"}; entries 2, 3). These results are mainly caused by interfragment long-range electrostatic interactions of Neu5Ac-Gal with charged amino acid residues.

###### 

The sums of IFIEs between human Neu5Acα(2-6)Gal with amino acid residues on avian and human H3 in the models **A** and **B** at the FMO-MP2/6-31G level

  Entry                  amino acid residues                                                      sum of IFIEs (kcal/mol)                             
  -------- ------------- ------------------------------------------------------------------------ --------------------------------------------------- ---------------------------------------------------
  **1**    model **A**   substituted residues (non-charge)[^\*1^](#TFN4-1){ref-type="table-fn"}   70.6                                                72.3
  **2**                  substituted residues (charge)[^\*2^](#TFN4-2){ref-type="table-fn"}       -16.7                                               1.2
  **3**                  Arg, Lys, His(P), Asp, Glu[^\*3^](#TFN4-3){ref-type="table-fn"}          71.2                                                40.2
  **4**                  terminal residues[^\*4^](#TFN4-4){ref-type="table-fn"}                   2.6                                                 0.3
  **5**                  others                                                                   108.1                                               105.9
  **6**                  total                                                                    235.8                                               219.9
           model **B**   model **A** range in model **B**                                                                                             
  **7**                  substituted residues (non-charge)[^\*1^](#TFN4-1){ref-type="table-fn"}   69.2(-1.4)[^\*10^](#TFN4-10){ref-type="table-fn"}   70.3(-2.0)[^\*10^](#TFN4-10){ref-type="table-fn"}
  **8**                  substituted residues (charge)[^\*2^](#TFN4-2){ref-type="table-fn"}       -16.8(-0.1)                                         1.2(0.0)
  **9**                  Arg, Lys, His(P), Asp, Glu[^\*5^](#TFN4-5){ref-type="table-fn"}          156.8(85.6)                                         158.3(118.1)
  **10**                 terminal residues[^\*6^](#TFN4-6){ref-type="table-fn"}                   6.3(3.7)                                            4.4(4.1)
  **11**                 others                                                                   79.3(-28.8)                                         73.7(-32.2)
  **12**                 total                                                                    294.8(59.0)                                         307.9(88.0)
                         model **B** range excluding model **A**                                                                                      
  **13**                 substituted residues (non-charge)[^\*7^](#TFN4-7){ref-type="table-fn"}   -0.2                                                -0.3
  **14**                 substituted residues (charge)[^\*8^](#TFN4-8){ref-type="table-fn"}       0.4                                                 -14.6
  **15**                 Arg, Lys, His(P), Asp, Glu[^\*5^](#TFN4-5){ref-type="table-fn"}          -67.4                                               -62.5
  **16**                 terminal residues[^\*9^](#TFN4-9){ref-type="table-fn"}                   4.2                                                 4.1
  **17**                 others                                                                   3.8                                                 1.5
  **18**                 total                                                                    -59.2                                               -71.8
  **19**                 model **B** total (entry 12+18)                                          235.6                                               236.1

amino acid positions are 137, 144, 145, 160, 182, 193, 226, 227, and 228

amino acid position is 158

their form are shown in [table 1](#T1){ref-type="table"}; model **A**

N- and C-terminal residues are charged +1 and −1, respectively ([table 1](#T1){ref-type="table"}; model **A**)

their form are shown in [table 1](#T1){ref-type="table"}; model **B**

the residues do not charged because they are parts of peptide chain in model **B**.

amino acid position is 102

amino acid positions are 63 and 92

N- and C-terminal residues are 62 and 263 as shown in [table 1](#T1){ref-type="table"}; model **B**

values in parenthesis are given by \[model **A**\]-\[model **A** range in model **B**\]

Changing the aspects of IFIEs analysis gives some guidance how much range (Å) around Neu5Ac-Gal analog in the gas phase HA1 complex is significant to evaluate sialsoside-HA1 interaction. The sums of interfragment interaction energies (s-IFIEs) between Neu5Acα(2-3 and 2-6)Gal and amino acid residues in the models **B** and **C** at the FMO-MP2/6-31G level are summarized in [Tables 5](#T5){ref-type="table"} and 6. s-IFIEs of amino acid residues within a 13Å radius around Neu5Ac-Gal were 41 to 43 kcal/mol larger than the s-IFIEs in model **A** range in the avian H3 complex ([Table 5](#T5){ref-type="table"}; entries 1 and 2, 5 and 6, [Table 6](#T6){ref-type="table"}; entries 11 and 12, 15 and 16), 24 kcal/mol larger in the human H3 complex ([Table 5](#T5){ref-type="table"}; entries 1 and 2, 5 and 6). Thus, model **A** is too small to evaluate the intermolecular stabilization. In our study, Neu5Ac-Gal analogs are charged −1, which strongly interacts with amino acids residues in 13Å radius around Neu5Ac-Gal by interfragment long-range electrostatic interactions. As some common factors in the partial model **B** and full model C, s-IFIEs within 13Å radius around Neu5Ac-Gal give similar values 358.4 and 357.3 kcal/mol in the avian H3-avian α2-3 complex ([Table 5](#T5){ref-type="table"}; entries 2, 6), 331.2 and 332.0 kcal/mol in the human H3-human 2-6 complex ([Table 6](#T6){ref-type="table"}; entries 2, 6), 324.8 and 323.7 kcal/mol in the avian Gln226Leu H3-human α2-6 complex ([Table 6](#T6){ref-type="table"}; entries 12, 16). Besides, the addition of IFIEs in charged amino acids to the s-IFIEs of the 13Å radius residues affords similar values to the corresponding s-IFIEs of all amino acids ([Table 5](#T5){ref-type="table"}; entries 3 and 4, 7 and 9, [Table 6](#T6){ref-type="table"}; entries 3 and 4, 7 and 10, 13 and 14, 17 and 19). In the full model C, the s-IFIEs of all amino acid residues are almost same with that of model **B** range ([Table 5](#T5){ref-type="table"}; entries 8, 9. [Table 6](#T6){ref-type="table"}; entries 8 and 9, 18 and 19). These results suggest that adequate IFIE analysis requires the amino acids in a 13Å radius around Neu5Ac-Gal in model **B**. In the human H3 model **C**, negative charged Asp2 and 7 un-stablize the complex to give slightly lower s-IFIEs 248.1 kcal/mol than s-IFIEs of Ser9-Lys326 ([Table 6](#T6){ref-type="table"}; entries 9, 10).

###### 

Sum of IFIEs between avian/human Neu5Acα(2-3 and 2-6)Gal and amino acid residues on avian H3 models **B** and **C** at the FMO-MP2/6-31G level

  Entry H3      model   amino acid residues                                           sum of IFIEs (kcal/mol)   Δ[^\*1^](#TFN5-1){ref-type="table-fn"}   
  ------------- ------- ------------------------------------------------------------- ------------------------- ---------------------------------------- ------
  **1** Avian   **B**   model **A**[^\*2^](#TFN5-2){ref-type="table-fn"}              317.5                     294.8                                    22.7
  **2**                 13Å[^\*3^](#TFN5-3){ref-type="table-fn"}                      358.4                     337.2                                    21.2
  **3**                 13Å + charged residues[^\*4^](#TFN5-4){ref-type="table-fn"}   260.4                     237.0                                    23.4
  **4**                 all (Arg62-Gly263)                                            258.6                     235.6                                    23.0
  **5**         **C**   model A[^\*2^](#TFN5-2){ref-type="table-fn"}                  316.4                     293.7                                    22.7
  **6**                 13Å[^\*3^](#TFN5-3){ref-type="table-fn"}                      357.3                     336.1                                    21.2
  **7**                 13Å + charged residues[^\*4^](#TFN5-4){ref-type="table-fn"}   251.9                     227.8                                    24.1
  **8**                 model **B** (Arg62-Gly263)                                    253.7                     230.7                                    23.0
  **9**                 all (Ser9-Lys326)                                             252.5                     228.7                                    23.8

Δ represents \[sum of IFIEs between avian α2-3 and amino acids\]-\[sum of IFIEs between human α2-6 and amino acids\].

model **A** consists of 70 amino acid residues (Asn96-Pro99, Gly129-Tyr161, Gly181-Val196, Asn216-Ile232, Figure 5)

Amino acid residues within 13Å radius around Neu5Ac-Gal are Pro74, Asn96-Pro99, Val130-Ser157, Tyr161, Leu164, Gly181-Gln197, Asn216-Pro221, Val223-Ile232, Asn250-Ala253, and Arg255.

Charged residues are listed in [table 1](#T1){ref-type="table"}

###### 

Sum of IFIEs between human Neu5Acα(2-6)Gal and amino acid residues on human Leu226 and avian Gln226Leu H3 models **B** and **C** at the FMO-MP2/6-31G level

  Entry H3                model   amino acid residues          human α2-6
  ----------------------- ------- ---------------------------- ------------
  **1** Human             **B**   model **A**                  307.9
  **2**                           13Å                          331.2
  **3**                           13Å + charged residues       238.9
  **4**                           all(Ile62-Gly263)            236.1
  **5**                   **C**   model **A**                  308.5
  **6**                           13Å                          332.0
  **7**                           13Å + charged residues       248.2
  **8**                           model **B** (Ile62-Gly263)   254.8
  **9**                           Ser9-Lys326                  255.0
  **10**                          all(Gln1-Thr328)             248.1
  **11** Aian Gln226Leu   **B**   model **A**                  282.4
  **12**                          13Å                          324.8
  **13**                          13Å + charged residues       224.2
  **14**                          all(Arg62-Gly263)            222.4
  **15**                  **C**   model **A**                  281.2
  **16**                          13Å                          323.7
  **17**                          13Å + charged residues       215.6
  **18**                          Arg62-Gly263                 217.5
  **19**                          all(Ser9-Lys326)             216.1

![Sequence alignments of avian and human H3 HA1 in the model complexes **A**, **B**, and **C**: Yellow; non-matching residue, green; weak matching residues, light blue; strong matching residue, brown; smallest binding site in the model **A**, purple; difference in the model **B** and **C**.](jmgm-03-133-g004){#F4}

Our IFIE analysis in the larger models **B** and **C** at the FMO-MP2/6-31G level confirms that avian H3 interacts with avian F2-3 receptor at 21 to 24 kcal/mol more strongly than with the human α2-6 receptor ([Table 5](#T5){ref-type="table"}; lineΔ). In the previous study, s-IFIEs of thirteen amino acid residues in the avian H3-avian α2-3 complex **A** is about 10 kcal/mol larger than that of avian H3-human α2-6 complex with a sensitive treatment of various charged residues ([@B29]). Thus we should evaluate the s-IFIEs in the larger models **B** or **C**. Comparing human H3-human α2-6 with avian Gln226Leu H3-human α2-6, the former has 25.5-27.3 kcal/mol larger s-IFIEs of the model **A** range ([Table 6](#T6){ref-type="table"}; entries 1 and 11, 5 and 15). The energy difference decreases in comparison with corresponding of the 13Å radius range ([Table 6](#T6){ref-type="table"}; entries 2 and 12, 6 and 16).

CONCLUSIONS
===========

Influenza viral H3 HA1 domains in complex with Neu5Acα(2-3 and 2-6)Gal analogs were studied at the FMO-MP2/6-31G level. Avian H3 bound to the avian-type receptor Neu5Acα(2-3)Gal 15.3 to 16.5 kcal/mol more strongly than to the human-type receptor Neu5Acα(2-6)Gal. Sialoside binding domain Arg(Ile)62-Gly263 (202 amino acids, avian H3; Arg62, human H3; Ile62) was enough size for estimating the binding energy of HA1 monomer-Neu5Ac-Gal disaccharide complex. We analyzed IFIEs between the Neu5Acα(2-3/6)Gal and amino acid residues on H3 HA1 to find that it is important to evaluate the IFIEs of amino acid residues within 13Å radius around Neu5Ac-Gal coupled with more accurate evaluation of long-range electrostatic interactions. These results demonstrated the relationships between the model sizes of HA1-sialoside complexes, their binding energies and sum of the IFIEs, then gave some guidance toward in silico prediction studies about HA-sialosides binding properties.
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HA

:   Hemagglutinin

Neu5Ac

:   α-N-acetyl-D-neuraminic acid

Gal

:   β-D-galactose

FMO

:   Fragment molecular orbital

MP2

:   Second-order Møller--Plesset perturbation

IFIE

:   Interfragment interaction energy

s-IFIEs

:   Sum of interfragment interaction energies
